Background: Ga-FAPI (fibroblast activation protein inhibitor) is a novel and highly promising radiotracer for PET/CT imaging. It has shown significant tumor uptake and high sensitivity in lesion detection across a range of cancer types. We aimed to compare the diagnostic value of Ga-FAPI and F-FDG PET/CT in common gynecological malignancies.
Methods: This retrospective study included 35 patients diagnosed with common gynecological tumors, including breast cancer, ovarian cancer, and cervical cancer. Among the 35 patients, 27 underwent PET/CT for the initial assessment of tumors, while 8 were assessed for recurrence detection. The median and range of tumor size and maximum standardized uptake values (SUV) were calculated.
Results: Thirty-five patients (median age, 57 years [interquartile range], 51-65 years) were evaluated. In treatment-naive patients (n = 27), Ga-FAPI PET/CT led to upstaging of the clinical TNM stage in five (19%) patients compared with F-FDG PET/CT. No significant difference in tracer uptake was observed between F-FDG and Ga-FAPI for primary lesions: breast cancer (7.2 vs. 4.9, P = 0.086), ovarian cancer (16.3 vs. 15.7, P = 0.345), and cervical cancer (18.3 vs. 17.1, P = 0.703). For involved lymph nodes, Ga-FAPI PET/CT demonstrated a higher SUV for breast cancer (9.9 vs. 6.1, P = 0.007) and cervical cancer (6.3 vs. 4.8, P = 0.048), while no significant difference was noted for ovarian cancer (7.0 vs. 5.9, P = 0.179). Furthermore, Ga-FAPI PET/CT demonstrated higher specificity and accuracy compared to F-FDG PET/CT for detecting metastatic lymph nodes (100% vs. 66%, P < 0.001; 94% vs. 80%, P < 0.001). In contrast, sensitivity did not differ significantly (97% vs. 86%, P = 0.125). For most distant metastases, Ga-FAPI exhibited a higher SUV than F-FDG in bone metastases (12.9 vs. 4.9, P = 0.036).
Conclusions: Ga-FAPI PET/CT demonstrated higher tracer uptake and was superior to F-FDG PET/CT in detecting primary and metastatic lesions in patients with common gynecological malignancies.
Trial Registration: ChiCTR, ChiCTR2100044131. Registered 10 October 2022, https://www.chictr.org.cn , ChiCTR2100044131.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869701 | PMC |
| http://dx.doi.org/10.1186/s40644-025-00843-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utilization of Gallium-68 Fibroblast Activation Protein Inhibitor Positron Emission Tomography (⁶⁸Ga-FAPI PET) for Head and Neck Malignancies With Neck Imaging Reporting and Data System (Ni-RADS) Correlation.
Cureus
February 2025
Department of Radiodiagnosis, Sri Devaraj Urs Medical College, Kolar, IND.
Background Head and neck cancers (HNCs) encompass a group of malignancies that arise in the mucosal surfaces of the oral cavity, pharynx, larynx, and other related structures. Advances in imaging modalities such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI) have improved tumor detection and staging, aiding in personalized treatment approaches. PET-CT is used to diagnose and stage various cancers.
View Article and Find Full Text PDFDifferences in Fibroinflammatory Activity Shown on Ga-FAPI-04 and F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease.
J Nucl Med
March 2025
Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, China;
IgG4-related disease (IgG4-RD) is a highly heterogeneous autoimmune disease. Recently, 2 subtypes of IgG4-RD, proliferative and fibrotic, were defined according to patients' clinicopathologic characteristics. The purpose of this study was to determine the difference in fibroinflammatory activity shown on Ga-FAPI-04 and F-FDG PET/CT in the proliferative and fibrotic IgG4-RD subtypes.
View Article and Find Full Text PDFComparison of [Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy.
J Nucl Med
March 2025
Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore;
Solitary fibrous tumor (SFT) is a rare sarcoma of mesenchymal origin. Although generally benign, SFTs carry the risk of recurrence and metastasis, with limited effective treatment options. The aims of this study are to compare the performance of fibroblast activation protein inhibitor (FAPI), [Ga]Ga-DOTA-FAPI-04 (denoted as [Ga]Ga-FAPI-04), and conventional [F]FDG PET/CT in patients with recurrent or metastatic SFTs head to head and to preliminarily explore the value of FAP-targeted radiopharmaceutical therapy with Lu for SFT patients.
View Article and Find Full Text PDFEfficacy of [Ga]Ga-FAPI-PET as a non-invasive evaluation method of liver fibrosis.
Ann Nucl Med
March 2025
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany.
Introduction: Liver fibrosis is a chronic fibrosing hepatic disorder following recurrent injury, characterized by the excessive accumulation of extracellular matrix. Early detection has a great clinical impact because 80-90% of hepatocellular carcinomas are known to develop in fibrotic or cirrhotic (end-stage fibrotic) livers. PET imaging with FAP ligands exhibited highly promising results in recent years to visualize fibrosis in various organs due to the crucial role of activated fibroblasts in fibrosing processes.
View Article and Find Full Text PDFHead-to-head comparison of F-FDG and Ga-FAPI PET/CT in common gynecological malignancies.
Cancer Imaging
February 2025
Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China.
Background: Ga-FAPI (fibroblast activation protein inhibitor) is a novel and highly promising radiotracer for PET/CT imaging. It has shown significant tumor uptake and high sensitivity in lesion detection across a range of cancer types. We aimed to compare the diagnostic value of Ga-FAPI and F-FDG PET/CT in common gynecological malignancies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!